Bad news for Alex and Pablo

NEW YORK, Jan 22, 2019 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lexicon Pharmaceuticals, Inc. ("Lexicon " or the "Company") LXRX, -3.52% Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/lxrx.

The investigation concerns whether Lexicon and certain of its officers and/or directors have violated federal securities laws.

On January 17, 2019, Lexicon announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration had "voted eight to eight on the question of whether the overall benefits of [Lexicon's product] Zynquista (sotagliflozin) outweighed the risks to support approval." On news of the advisory committee's stalemate, Lexicon's stock price fell $1.74 per share, or 22.6%, to close at $5.96 per share on January 18, 2019.

If you are aware of any facts relating to this investigation, or purchased Lexicon shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/lxrx. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

 

Ruh roh. They talk so much shit at home office I bet a lot of them will be going down.